HWAM
NVCR icon

Hennion & Walsh Asset Management’s NovoCure NVCR Stock Holding History

Hennion & Walsh Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$824K Sell
54,414
-477
-0.9% -$7.22K 0.02% 619
2026
Q1 		$598K Buy
54,891
+646
+1% +$8.07K 0.02% 666
2025
Q4 		$701K Buy
54,245
+12,915
+31% +$166K 0.02% 613
2025
Q3 		$534K Buy
41,330
+17,010
+70% +$227K 0.02% 690
2025
Q2 		$433K Buy
+24,320
New +$424K 0.02% 715

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Hennion & Walsh Asset Management's NVCR Position: Q2 2026 in Review

Hennion & Walsh Asset Management reduced its NovoCure (NVCR) stake by 0.87% in Q2 2026, selling an estimated $7.22K and leaving 54,414 shares worth $824K. The position accounts for 0.02% of the portfolio, ranked #619.

Hennion & Walsh Asset Management first reported a position in NVCR in Q2 2025 and has held it in 5 quarters since. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Hennion & Walsh Asset Management held 54,414 shares of NovoCure worth $824K as of Q2 2026.
  • Hennion & Walsh Asset Management sold 477 NovoCure shares in Q2 2026, an estimated $7.22K.
  • NovoCure made up 0.02% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #619 holding.
  • Hennion & Walsh Asset Management first reported a position in NovoCure in Q2 2025 and has held it in 5 quarters since.
  • 216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.